Factor Bioscience Inc., a biotechnology company based in Cambridge, Massachusetts, has announced the addition of three new members to its translational science team. Led by Kyle Garland, Ph.D., who will serve as the Director of Translational Science, the team includes Associate Scientists Raven Hinkel and Elizabeth Belcher. Dr. Matt Angel, Co-Founder, Chairman, and CEO of Factor, expressed excitement about welcoming these talented scientific professionals to the team, highlighting their expertise in mRNA and cell engineering.
Dr. Garland expressed his belief in the potential of Factor’s mRNA and cell-engineering technologies to revolutionize biotechnology research and development. He looks forward to collaborating with Drs. Angel and Rohde to translate these technologies into new products. Prior to joining Factor, Dr. Garland led the Department of Research and Development at Eterna Therapeutics.
Factor Bioscience focuses on developing technologies to engineer cells for improving health and quality of life. With a background in Chemical Engineering and Bioengineering from Vanderbilt University and Lehigh University, Dr. Garland brings a wealth of experience to Factor’s translational science team. The new team members bring experience in various scientific fields such as synthetic mRNA, mRNA cell reprogramming, gene editing, cell manufacturing, immunoengineering, and nucleic acid formulation. Dr Christopher Rohde emphasized that the diverse backgrounds and skills that the new team members bring are an asset to the company’s growth
